InvestorsHub Logo
Followers 657
Posts 83634
Boards Moderated 0
Alias Born 05/25/2008

Re: sal32647 post# 123

Friday, 06/09/2023 12:06:00 AM

Friday, June 09, 2023 12:06:00 AM

Post# of 230
- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, and Investigator Global Assessment (IGA) -

- DMT310 significantly reduced inflammatory lesions by 45% after only 4 treatments in patients with moderate-to-severe acne -

- FDA responses to DMT310 End of Phase 2 meeting package expected by the end this month -

SAN DIEGO, CA / ACCESSWIRE / June 8, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("De
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DRMA News